Stent Plus Atrial Fibrillation: How Long on Three Drugs
A single patient who now needs both an anticoagulant and an antiplatelet regimen, and both teams agree on that much immediately. What isn't agreed is how many days of overlap her fresh stent actually needs before the third drug comes off.
M.G., a 75-year-old woman, has shared an apartment with her younger sister since the two of them were widowed within a year of each other, and still splits the crossword with her most mornings over coffee before either of them has gotten properly dressed. Her hypertension has been well controlled for years on a single agent, and she has known paroxysmal atrial fibrillation, diagnosed four years ago, that her previous cardiologist judged too infrequent and too low-risk to warrant anticoagulation at the time. She came to the emergency department two days ago with chest pressure and was found to have an NSTEMI; coronary angiography showed a significant right coronary lesion, treated with a drug-eluting stent.
Her CHA2DS2-VASc score, recalculated on this admission, comes to 5 — two points for her age alone, one for female sex, one for hypertension, and one for the coronary disease this admission just documented — high enough that deferring anticoagulation is no longer defensible the way it may have looked four years ago with fewer risk factors accumulated. She now needs both a P2Y12 inhibitor for her fresh stent and an anticoagulant for her atrial fibrillation, and the real question isn't whether she gets both — she does — it's how long she stays on three antithrombotic drugs at once before dropping to two, and which two those should be. Trial data in exactly this population — AUGUSTUS chief among them — found that dropping aspirin early and continuing a direct oral anticoagulant alongside a single P2Y12 inhibitor reduced bleeding substantially without a corresponding rise in stent thrombosis or ischemic stroke.
How many days of overlap
Drop the aspirin within the first week and keep her on clopidogrel plus apixaban alone. AUGUSTUS looked at essentially this population — atrial fibrillation plus a recent ACS or PCI — and found that a DOAC plus a single P2Y12 inhibitor, without aspirin, produced substantially less bleeding than triple therapy, without an increase in death, stroke, or stent thrombosis. There's no ischemic benefit left on the table by dropping aspirin early; there's only bleeding risk being carried for nothing.
I'd keep her on aspirin a little longer than a week — not months, just past the point where acute stent thrombosis risk is highest, which is concentrated in the first several days after implantation. Her lesion was a genuinely significant right coronary stenosis, not an incidental finding, and I want the early window covered before we drop to dual therapy.
This isn't a disagreement about the destination — dual therapy, dropping aspirin, is where both of us are headed. It's a disagreement about exactly which day that happens on, and I don't think AUGUSTUS's data are precise enough to settle that particular week-by-week question either way.
Two things worth being explicit about while we finalize this. First, she gets full-dose apixaban, 5 mg twice daily. The dose-reduction criteria are age 80 or older, weight 60 kg or less, and creatinine 1.5 mg/dL or higher — two of those three, and eGFR is not one of them. She is 75, 68 kg, and her creatinine is 1.0, so she meets none. A reduced dose here would be underdosing her against the stroke risk we just decided to treat, which is the commoner error in this exact situation. Second, clopidogrel is the right P2Y12 partner here, not ticagrelor or prasugrel — neither of the more potent agents is established alongside a chronic anticoagulant the way clopidogrel is, and using one of them in this combination would be trading a documented bleeding profile for an undocumented one.
Full-dose apixaban started; clopidogrel continued; aspirin continued through the first week after PCI and then discontinued, leaving her on dual therapy — apixaban plus clopidogrel — alone thereafter. A compromise on timing, not on the destination, which both cardiology voices had agreed on from the start.